Nine field trials were conducted to determine the efficacy of sarafloxacin-hydrochloride in the treatment of naturally and experimentally induced infections of Edwardsiella ictaluri in channel catfish. Six trials were terminated prior to completion for various reasons beyond our control, i.e., mink and muskrat damage, wide temperature fluctuations outside the Edwardsiella ictaluri temperature window, and the non­occurrence of naturally and experimentally induced Edwardsiella ictaluri infections. In the three complete trials (numbers 6, 8, and 9), sarafloxacin-hydrochloride in the feed proved efficacious in treating channel catfish infected with Edwardsiella ictaluri. In field trial 6 sarafloxacin-hydrochloride significantly (P<0.05) increased the average percent survival from 43X in unmedicated fish to 69% in the fish receiving the sarafloxacin-hydrochloride medicated feed. Similar results were also found in field trial 8 where sarafloxacin-hydrochloride significantly (P<0.05) increased the average percent survival from 11% in unmedicated fish to 48% in the fish receiving the sarafloxacin-hydrochloride medicated feed. The results were similar in field trial 9, in which sarafloxacin-hydrochloride significantly (P<0.05) increased the percent survival from 58% in unmedicated fish to 73% in the fish receiving the sarafloxacin-hydrochloride medicated feed. In field trial 9, Romet was tested. Romet medicated feed fed at twice the recommended dose increased the average percent survival to 82%. The Romet medicated feed fed at twice the recommended dosage significantly (P<0.05) increased percent survival when compared to fingerlings fed both the non-medicated feed and sarafloxacin-hydrochloride medicated feed.